APA

Ko A. H., Tempero M. A., Shan Y., Su W., Lin Y., Dito E., Ong A., Wang Y., Yeh C. G. & Chen L. (20131104). A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. : British journal of cancer.

Chicago

Ko A H, Tempero M A, Shan Y-S, Su W-C, Lin Y-L, Dito E, Ong A, Wang Y-W, Yeh C G and Chen L-T. 20131104. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. : British journal of cancer.

Harvard

Ko A. H., Tempero M. A., Shan Y., Su W., Lin Y., Dito E., Ong A., Wang Y., Yeh C. G. and Chen L. (20131104). A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. : British journal of cancer.

MLA

Ko A H, Tempero M A, Shan Y-S, Su W-C, Lin Y-L, Dito E, Ong A, Wang Y-W, Yeh C G and Chen L-T. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. : British journal of cancer. 20131104.